Case report: Durable response to ruxolitinib in a child with TREX1-related disorder

BACKGROUND: JAK inhibitors are useful in treating interferonopathies, presumably because they downregulate the JAK/STAT signaling. There are limited studies about the safety and effectiveness of using JAK inhibitors in children with TREX1-related disorders. CASE PRESENTATION: We report an 8-year-old...

Descripción completa

Detalles Bibliográficos
Autores principales: Bin Khathlan, Yasir, Almutairi, Sajdi, Albadr, Fahad B., Alangari, Abdullah A., Alsultan, Abdulrahman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175768/
https://www.ncbi.nlm.nih.gov/pubmed/37187582
http://dx.doi.org/10.3389/fped.2023.1178919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175768/
https://www.ncbi.nlm.nih.gov/pubmed/37187582
http://dx.doi.org/10.3389/fped.2023.1178919

Ejemplares similares